ReviewPharmaceutics2021
3D Printing of Pharmaceutical Application: Drug Screening and Drug Delivery.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Current 3D Printing Technologies and their Potential Applications in Drug Delivery, Personalized Medicine & Pharmaceutical Sciences.Current drug discovery technologies · 2026Review
- 3D Hybrid Bioprinting for Complex Multi-Tissue Engineering.bioRxiv : the preprint server for biology · 2025Article
- 3D-printing of dipyridamole/thermoplastic polyurethane materials for bone regeneration.Drug delivery and translational research · 2025Article
- Functional Liver Cell-Based Platforms in Biomedical Research.Pharmacology research & perspectives · 2025Review
- The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals.Pharmaceutics · 2025Review
- Extrusion bioprinting: meeting the promise of human tissue biofabrication?Progress in biomedical engineering (Bristol, England) · 2025Review
- Targeting immune cell migration as therapy for inflammatory disease: a review.Frontiers in immunology · 2025Review
- 3D bioprinting for the construction of drug testing models-development strategies and regulatory concerns.Frontiers in bioengineering and biotechnology · 2025Review
- Photocrosslinkable Biomaterials for 3D Bioprinting: Mechanisms, Recent Advances, and Future Prospects.International journal of molecular sciences · 2024Review
- 3D Bioprinting in Cancer Modeling and Biomedicine: From Print Categories to Biological Applications.ACS omega · 2024Review
- The cutting-edge progress in bioprinting for biomedicine: principles, applications, and future perspectives.MedComm · 2024Review
- (3D) Bioprinting-Next Dimension of the Pharmaceutical Sector.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Review
- Advancement in Cancer Vasculogenesis Modeling through 3D Bioprinting Technology.Biomimetics (Basel, Switzerland) · 2024Review
- Applications of 3D Bioprinting Technology to Brain Cells and Brain Tumor Models: Special Emphasis to Glioblastoma.ACS biomaterials science & engineering · 2024Review
- How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.International journal of nanomedicine · 2024Review
- Review on Recent Advance of 3DP-Based Pediatric Drug Formulations.BioMed research international · 2024Review
- Cell type specification and diversity in subpallial organoids.Frontiers in genetics · 2024Review
- 4D Printing: The Development of Responsive Materials Using 3D-Printing Technology.Pharmaceutics · 2023Review
- Development of Biocompatible 3D-Printed Artificial Blood Vessels through Multidimensional Approaches.Journal of functional biomaterials · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Advances in three-dimensional (3D) printing techniques and the development of tailored biomaterials have facilitated the precise fabrication of biological components and complex 3D geometrics over the past few decades. Moreover, the notable growth of 3D printing has facilitated pharmaceutical applications, enabling the development of customized drug screening and drug delivery systems for individual patients, breaking away from conventional approaches that primarily rely on transgenic animal experiments and mass production. This review provides an extensive overview of 3D printing research applied to drug screening and drug delivery systems that represent pharmaceutical applications. We classify several elements required by each application for advanced pharmaceutical techniques and briefly describe state-of-the-art 3D printing technology consisting of cells, bioinks, and printing strategies that satisfy requirements. Furthermore, we discuss the limitations of traditional approaches by providing concrete examples of drug screening (organoid, organ-on-a-chip, and tissue/organ equivalent) and drug delivery systems (oral/vaginal/rectal and transdermal/surgical drug delivery), followed by the introduction of recent pharmaceutical investigations using 3D printing-based strategies to overcome these challenges.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.